Abbott (NYSE:ABT) today announced a significant milestone abroad with the opening of a new manufacturing facility in Ireland.

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Clinics and health systems using Tidepool+ will be able to initiate the connection with their patients using FreeStyle Libre ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to ...